Abbott to use Liquidia nanotechnology for RNA-based cancer drugs
Abbott Laboratories has agreed to license Liquidia Technologies' PRINT nanoparticle technology to help deliver siRNA therapies directly to cancer cells. The companies did not disclose financial details of the deal, which Liquidia CEO Neal Fowler says gives "validation" to the PRINT platform.
American City Business Journals | 01/07
This story published in BIO SmartBrief on 01/08/2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|